These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

824 related articles for article (PubMed ID: 30352902)

  • 21. Clinical Outcome of ALK-Positive Non-Small Cell Lung Cancer (NSCLC) Patients with De Novo EGFR or KRAS Co-Mutations Receiving Tyrosine Kinase Inhibitors (TKIs).
    Schmid S; Gautschi O; Rothschild S; Mark M; Froesch P; Klingbiel D; Reichegger H; Jochum W; Diebold J; Früh M
    J Thorac Oncol; 2017 Apr; 12(4):681-688. PubMed ID: 28007627
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Landscape and Clonal Dominance of Co-occurring Genomic Alterations in Non-Small-Cell Lung Cancer Harboring
    Le X; Hong L; Hensel C; Chen R; Kemp H; Coleman N; Ciunci CA; Liu SV; Negrao MV; Yen J; Xia X; Scheuenpflug J; Stroh C; Juraeva D; Tsao A; Hong D; Raymond V; Paik P; Zhang J; Heymach JV
    JCO Precis Oncol; 2021; 5():. PubMed ID: 34957368
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Acquired KRAS mutation and loss of low-level MET amplification after durable response to crizotinib in a patient with lung adenocarcinoma.
    Riedel R; Michels S; Heydt C; Siemanowski J; Kobe C; Bunck A; Schäfer S; Fischer RN; Scheffler M; Abdulla DSY; Nogová L; Koleczko S; Merkelbach-Bruse S; Büttner R; Wolf J
    Lung Cancer; 2019 Jul; 133():20-22. PubMed ID: 31200822
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Molecular Diagnostic Assays and Clinicopathologic Implications of MET Exon 14 Skipping Mutation in Non-small-cell Lung Cancer.
    Kim EK; Kim KA; Lee CY; Kim S; Chang S; Cho BC; Shim HS
    Clin Lung Cancer; 2019 Jan; 20(1):e123-e132. PubMed ID: 30391211
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Identification of MET exon14 skipping by targeted DNA- and RNA-based next-generation sequencing in pulmonary sarcomatoid carcinomas.
    Li Y; Gao L; Ma D; Qiu T; Li W; Li W; Guo L; Xing P; Liu B; Deng L; Fu J; Li J; Yu Y; Ying J
    Lung Cancer; 2018 Aug; 122():113-119. PubMed ID: 30032818
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors.
    Frampton GM; Ali SM; Rosenzweig M; Chmielecki J; Lu X; Bauer TM; Akimov M; Bufill JA; Lee C; Jentz D; Hoover R; Ou SH; Salgia R; Brennan T; Chalmers ZR; Jaeger S; Huang A; Elvin JA; Erlich R; Fichtenholtz A; Gowen KA; Greenbowe J; Johnson A; Khaira D; McMahon C; Sanford EM; Roels S; White J; Greshock J; Schlegel R; Lipson D; Yelensky R; Morosini D; Ross JS; Collisson E; Peters M; Stephens PJ; Miller VA
    Cancer Discov; 2015 Aug; 5(8):850-9. PubMed ID: 25971938
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A Ras destabilizer KYA1797K overcomes the resistance of EGFR tyrosine kinase inhibitor in KRAS-mutated non-small cell lung cancer.
    Park J; Cho YH; Shin WJ; Lee SK; Lee J; Kim T; Cha PH; Yang JS; Cho J; Min DS; Han G; Lee HY; Choi KY
    Sci Rep; 2019 Jan; 9(1):648. PubMed ID: 30679620
    [TBL] [Abstract][Full Text] [Related]  

  • 28. p65BTK is a novel potential actionable target in KRAS-mutated/EGFR-wild type lung adenocarcinoma.
    Giordano F; Vaira V; Cortinovis D; Bonomo S; Goedmakers J; Brena F; Cialdella A; Ianzano L; Forno I; Cerrito MG; Giovannoni R; Ferri GL; Tasciotti E; Vicent S; Damarco F; Bosari S; Lavitrano M; Grassilli E
    J Exp Clin Cancer Res; 2019 Jun; 38(1):260. PubMed ID: 31200752
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A lung adenocarcinoma patient with co-mutations of MET and EGFR exon20 insertion responded to crizotinib.
    Chen Y; Jiang B; He Y; Zhang C; Zhou W; Fang C; Gu D; Zhang M; Ji M; Shi J; Yang X
    BMC Med Genomics; 2022 Jun; 15(1):141. PubMed ID: 35739536
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mutations in the MET tyrosine kinase domain and resistance to tyrosine kinase inhibitors in non-small-cell lung cancer.
    Yao Y; Yang H; Zhu B; Wang S; Pang J; Wu X; Xu Y; Zhang J; Zhang J; Ou Q; Tian H; Zhao Z
    Respir Res; 2023 Jan; 24(1):28. PubMed ID: 36698189
    [TBL] [Abstract][Full Text] [Related]  

  • 31. PAI-1 mediates acquired resistance to MET-targeted therapy in non-small cell lung cancer.
    Thu YM; Suzawa K; Tomida S; Ochi K; Tsudaka S; Takatsu F; Date K; Matsuda N; Iwata K; Nakata K; Shien K; Yamamoto H; Okazaki M; Sugimoto S; Toyooka S
    PLoS One; 2024; 19(5):e0300644. PubMed ID: 38758826
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prolonged MEK inhibition leads to acquired resistance and increased invasiveness in KRAS mutant gastric cancer.
    Choi KM; Cho E; Kim E; Shin JH; Kang M; Kim B; Han EH; Chung YH; Kim JY
    Biochem Biophys Res Commun; 2018 Dec; 507(1-4):311-318. PubMed ID: 30466782
    [TBL] [Abstract][Full Text] [Related]  

  • 33. MicroRNA-16 Restores Sensitivity to Tyrosine Kinase Inhibitors and Outperforms MEK Inhibitors in
    Fanini F; Bandini E; Plousiou M; Carloni S; Wise P; Neviani P; Murtadha M; Foca F; Fabbri F; Vannini I; Fabbri M
    Int J Mol Sci; 2021 Dec; 22(24):. PubMed ID: 34948154
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Management and future directions in non-small cell lung cancer with known activating mutations.
    Gerber DE; Gandhi L; Costa DB
    Am Soc Clin Oncol Educ Book; 2014; ():e353-65. PubMed ID: 24857124
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Predictive value of oncogenic driver subtype, programmed death-1 ligand (PD-L1) score, and smoking status on the efficacy of PD-1/PD-L1 inhibitors in patients with oncogene-driven non-small cell lung cancer.
    Ng TL; Liu Y; Dimou A; Patil T; Aisner DL; Dong Z; Jiang T; Su C; Wu C; Ren S; Zhou C; Camidge DR
    Cancer; 2019 Apr; 125(7):1038-1049. PubMed ID: 30548240
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Distinct Afatinib Resistance Mechanisms Identified in Lung Adenocarcinoma Harboring an EGFR Mutation.
    Yamaoka T; Ohmori T; Ohba M; Arata S; Murata Y; Kusumoto S; Ando K; Ishida H; Ohnishi T; Sasaki Y
    Mol Cancer Res; 2017 Jul; 15(7):915-928. PubMed ID: 28289161
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inhibition of ABCB1 Overcomes Cancer Stem Cell-like Properties and Acquired Resistance to MET Inhibitors in Non-Small Cell Lung Cancer.
    Sugano T; Seike M; Noro R; Soeno C; Chiba M; Zou F; Nakamichi S; Nishijima N; Matsumoto M; Miyanaga A; Kubota K; Gemma A
    Mol Cancer Ther; 2015 Nov; 14(11):2433-40. PubMed ID: 26351321
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Influence of EGFR-activating mutations on sensitivity to tyrosine kinase inhibitors in a KRAS mutant non-small cell lung cancer cell line.
    Tsukumo Y; Naito M; Suzuki T
    PLoS One; 2020; 15(3):e0229712. PubMed ID: 32130260
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Combination Therapy With MDM2 and MEK Inhibitors Is Effective in Patient-Derived Models of Lung Adenocarcinoma With Concurrent Oncogenic Drivers and MDM2 Amplification.
    Elkrief A; Odintsov I; Markov V; Caeser R; Sobczuk P; Tischfield SE; Bhanot U; Vanderbilt CM; Cheng EH; Drilon A; Riely GJ; Lockwood WW; de Stanchina E; Tirunagaru VG; Doebele RC; Quintanal-Villalonga Á; Rudin CM; Somwar R; Ladanyi M
    J Thorac Oncol; 2023 Sep; 18(9):1165-1183. PubMed ID: 37182602
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of the genomic background of MET-altered carcinomas of the lung: biological differences and analogies.
    Castiglione R; Alidousty C; Holz B; Wagener S; Baar T; Heydt C; Binot E; Zupp S; Kron A; Wolf J; Merkelbach-Bruse S; Reinhardt HC; Buettner R; Schultheis AM
    Mod Pathol; 2019 May; 32(5):627-638. PubMed ID: 30459450
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 42.